Q-omics provides the consensus-scored CHAF1B profile across patient tissues and cancer cell-line models. CHAF1B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHAF1B is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, CHAF1B protein abundance shows 29,052 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where CHAF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHAF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHAF1B survival associations across molecular data types. CHAF1B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHAF1B RNA expression–survival associations across cancer types. High CHAF1B expression shows unfavorable associations in ACC, KIRP, MESO, LIHC and KICH, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHAF1B RNA expression.
This table summarizes CHAF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CHAF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHAF1B shows higher tumor expression in BLCA, COAD, HNSC, THCA, LUAD and LIHC. The BLCA box plot shows higher CHAF1B RNA expression in tumor versus normal tissue (log2 FC = +2.031, t-test p < 0.001).
This table shows molecular features associated with CHAF1B in patient tissues and cancer cell lines. In patient samples, CHAF1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHAF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
